The Significance of the “KGS Practice” in Pathology and Oncology Part 1
PART 1: ABSTRACT
In oncohistopathology and oncobiopathology today, various systems of measurement, appraisal, assessment and evaluation of tumor cells’ phenotypic characteristics, in vivo, are used to gather or complement data in clinical and research work. Mostly being two or three-tier scale systems based on the main histologic characteristics of cells, often including the parameters of cell differentiation nuclear size/pleomorphism, mitotic activity, tumor necrosis and proportion of solid growth and pattern of invasion, they are practically useful, but they have limited boundaries of usage in terms of interpretation and application in both clinical and research medicine, and they lack the levels of provision and contentment we critically need in research studies, case discussions, patient files, pathology reports and medical communications and transactions, and for preparing and conducting suitable and efficient oncotherapy. As we continue to use these grading systems in clinical practice and research today, we feel the vital need of a thorough, large-in-scope and all-embracing single universal grading system that we can more comprehensively and reproducibly use in clinical and research oncology and other medical fields. In this article, I present the “Karindas Grading System” (KGS), the new, wide-ranging, robust and comprehensive single cellular and tissue grading system which brings a new all-encompassing universal paradigm for observing and evaluating the phenotypic and genotypic identities of human cells, in vivo, as well as the identities of the tissues they belong to.
© 2010-2015 Dr. M.M. Karindas, MD